Janis M Dionne1, Kelvin Lou, Lee Er, Kathleen Collin, Colin T White. 1. Department of Pediatrics, Division of Nephrology, BC Children's Hospital, University of British Columbia, 4480 Oak Street, Vancouver, BC, V6H 3V4, Canada. jdionne@cw.bc.ca
Abstract
BACKGROUND: Chronic kidney disease (CKD) is associated with significant economic burdens to both patients and the healthcare system, but pharmaceutical cost analyses are uncommon despite drug therapy being a cornerstone of CKD management. METHODS: This observational, retrospective review of drug cost distribution at a single tertiary care pediatric nephrology program in Canada was conducted on prevalent patients with CKD aged 1 month to 20 years, between 1 January and 31 December 2009. RESULTS: The time-adjusted annual pharmaceutical cost of our cohort (n = 148) was just below US $250,000 with a cost per patient per year of $1,800. The highest costs were in the growth and nutrition category, followed by anemia, hypertension and bone metabolism. Total drug cost per patient increased as CKD stage advanced. Adherence was not demonstrated in any drug category, and the mean daily pill burden was nine (range 2-23). CONCLUSIONS: This study has shown that while the annual pharmaceutical costs on a per patient basis are similar between children and adults, the cost distribution is very different. An increase in awareness of the unique needs of the pediatric population should allow for more cost-effective financial planning in pediatric CKD clinics.
BACKGROUND:Chronic kidney disease (CKD) is associated with significant economic burdens to both patients and the healthcare system, but pharmaceutical cost analyses are uncommon despite drug therapy being a cornerstone of CKD management. METHODS: This observational, retrospective review of drug cost distribution at a single tertiary care pediatric nephrology program in Canada was conducted on prevalent patients with CKD aged 1 month to 20 years, between 1 January and 31 December 2009. RESULTS: The time-adjusted annual pharmaceutical cost of our cohort (n = 148) was just below US $250,000 with a cost per patient per year of $1,800. The highest costs were in the growth and nutrition category, followed by anemia, hypertension and bone metabolism. Total drug cost per patient increased as CKD stage advanced. Adherence was not demonstrated in any drug category, and the mean daily pill burden was nine (range 2-23). CONCLUSIONS: This study has shown that while the annual pharmaceutical costs on a per patient basis are similar between children and adults, the cost distribution is very different. An increase in awareness of the unique needs of the pediatric population should allow for more cost-effective financial planning in pediatric CKD clinics.
Authors: R Pons; E Torregrosa; J Hernáindez-Jaras; H García; A Ríus; C Calvo; J Sánchez-Canel; M Pin; F Maduell Journal: Nefrologia Date: 2006 Impact factor: 2.033
Authors: George R Bailie; George Eisele; Lei Liu; Erik Roys; Margaret Kiser; Frederick Finkelstein; Robert Wolfe; Friedrich Port; Sally Burrows-Hudson; Rajiv Saran Journal: Nephrol Dial Transplant Date: 2005-03-15 Impact factor: 5.992
Authors: Jeffrey J Fadrowski; Christopher B Pierce; Stephen R Cole; Marva Moxey-Mims; Bradley A Warady; Susan L Furth Journal: Clin J Am Soc Nephrol Date: 2008-01-30 Impact factor: 8.237
Authors: Oleh M Akchurin; Michael F Schneider; Lucy Mulqueen; Ellen R Brooks; Craig B Langman; Larry A Greenbaum; Susan L Furth; Marva Moxey-Mims; Bradley A Warady; Frederick J Kaskel; Amy L Skversky Journal: Clin J Am Soc Nephrol Date: 2014-06-26 Impact factor: 8.237